Abstract
PPAR
PPAR
M. A. Socinski, “Combined modality trials in unresectable stage III non-small cell lung cancer: the cancer and leukemia group B experience,” Seminars in Oncology, vol. 32, 3, pp. S114–S118, 2005.
View at: Publisher Site | Google ScholarC. A. Granville and P. A. Dennis, “An overview of lung cancer genomics and proteomics,” American Journal of Respiratory Cell and Molecular Biology, vol. 32, no. 3, pp. 169–176, 2005.
View at: Publisher Site | Google ScholarS. A. Kliewer, K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans, “Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors,” Nature, vol. 358, no. 6389, pp. 771–774, 1992.
View at: Publisher Site | Google ScholarS. Schmidt, E. Moric, M. Schmidt, M. Sastre, D. L. Feinstein, and M. T. Heneka, “Anti-inflammatory and antiproliferative actions of PPAR- agonists on T lymphocytes derived from MS patients,” Journal of Leukocyte Biology, vol. 75, no. 3, pp. 478–485, 2004.
View at: Publisher Site | Google ScholarN. Hirase, T. Yanase, Y.-M. Mu et al., “Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60,” Oncology, vol. 57, 2, pp. 17–26, 1999.
View at: Publisher Site | Google ScholarC. Grommes, G. E. Landreth, and M. T. Heneka, “Antineoplastic effects of peroxisome proliferatoractivated receptor agonists,” The Lancet Oncology, vol. 5, no. 7, pp. 419–429, 2004.
View at: Publisher Site | Google ScholarS. Theocharis, H. Kanelli, E. Politi et al., “Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade,” Lung Cancer, vol. 36, no. 3, pp. 249–255, 2002.
View at: Publisher Site | Google ScholarT. Satoh, M. Toyoda, H. Hoshino et al., “Activation of peroxisome proliferator-activated receptor- stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells,” Oncogene, vol. 21, no. 14, pp. 2171–2180, 2002.
View at: Publisher Site | Google ScholarS. Han, N. Sidell, P. B. Fisher, and J. Roman, “Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor in human lung carcinoma cells,” Clinical Cancer Research, vol. 10, no. 6, pp. 1911–1919, 2004.
View at: Publisher Site | Google ScholarV. G. Keshamouni, R. C. Reddy, D. A. Arenberg et al., “Peroxisome proliferator-activated receptor- activation inhibits tumor progression in non-small-cell lung cancer,” Oncogene, vol. 23, no. 1, pp. 100–108, 2004.
View at: Publisher Site | Google ScholarS. Han and J. Roman, “Rosiglitazone suppresses human lung carcinoma cell growth through PPAR-dependent and PPAR-independent signal pathways,” Molecular Cancer Therapeutics, vol. 5, no. 2, pp. 430–437, 2006.
View at: Publisher Site | Google ScholarX. Wang, A. Beugnet, M. Murakami, S. Yamanaka, and C. G. Proud, “Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins,” Molecular and Cellular Biology, vol. 25, no. 7, pp. 2558–2572, 2005.
View at: Publisher Site | Google ScholarY. Li, M. N. Corradetti, K. Inoki, and K.-L. Guan, “TSC2: filling the GAP in the mTOR signaling pathway,” Trends in Biochemical Sciences, vol. 29, no. 1, pp. 32–38, 2004.
View at: Publisher Site | Google ScholarS. Han, N. Sidell, S. Roser-Page, and J. Roman, “Fibronectin stimulates human lung carcinoma cell growth by inducing cyclooxygenase-2 (COX-2) expression,” International Journal of Cancer, vol. 111, no. 3, pp. 322–331, 2004.
View at: Publisher Site | Google ScholarS. Han, Z. M. Lei, and C. V. Rao, “Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin during the differentiation of human endometrial stromal cells into decidua,” Endocrinology, vol. 137, no. 5, pp. 1791–1797, 1996.
View at: Publisher Site | Google ScholarJ. J. Schlezinger, J. K. Emberley, and D. H. Sherr, “Activation of multiple mitogen-activated protein kinases in pro/pre-B cells by GW7845, a peroxisome proliferator-activated receptor agonist, and their contribution to GW7845-induced apoptosis,” Toxicological Sciences, vol. 92, no. 2, pp. 433–444, 2006.
View at: Publisher Site | Google ScholarM. Li, T. W. Lee, T. S. K. Mok, T. D. Warner, A. P. C. Yim, and G. G. Chen, “Activation of peroxisome proliferator-activated receptor- by troglitazone (TGZ) inhibits human lung cell growth,” Journal of Cellular Biochemistry, vol. 96, no. 4, pp. 760–774, 2005.
View at: Publisher Site | Google ScholarY. Li, K. Inoki, P. Vacratsis, and K.-L. Guan, “The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3,” Journal of Biological Chemistry, vol. 278, no. 16, pp. 13663–13671, 2003.
View at: Publisher Site | Google ScholarJ. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995.
View at: Publisher Site | Google ScholarA. Galli, E. Ceni, D. W. Crabb et al., “Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR independent mechanisms,” Gut, vol. 53, no. 11, pp. 1688–1697, 2004.
View at: Publisher Site | Google ScholarC.-W. Shiau, C.-C. Yang, S. K. Kulp et al., “Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPAR,” Cancer Research, vol. 65, no. 4, pp. 1561–1569, 2005.
View at: Publisher Site | Google ScholarU. Valentiner, M. Carlsson, R. Erttmann, H. Hildebrandt, and U. Schumacher, “Ligands for the peroxisome proliferator-activated receptor- have inhibitory effects on growth of human neuroblastoma cells in vitro,” Toxicology, vol. 213, no. 1-2, pp. 157–168, 2005.
View at: Publisher Site | Google ScholarP. Ferruzzi, E. Ceni, M. Tarocchi et al., “Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 3, pp. 1332–1339, 2005.
View at: Publisher Site | Google ScholarS.-I. Kawaguchi, K. Harada, Supriatno, H. Yoshida, and M. Sato, “Overexpression of tuberous sclerosis complex 2 exerts antitumor effect on oral cancer cell lines,” Oral Oncology, vol. 39, no. 8, pp. 836–841, 2003.
View at: Publisher Site | Google ScholarA. Y. Choo, P. P. Roux, and J. Blenis, “Mind the GAP: Wnt steps onto the mTORC1 train,” Cell, vol. 126, no. 5, pp. 834–836, 2006.
View at: Publisher Site | Google ScholarC. J. Potter, L. G. Pedraza, and T. Xu, “Akt regulates growth by directly phosphorylating Tsc2,” Nature Cell Biology, vol. 4, no. 9, pp. 658–665, 2002.
View at: Publisher Site | Google ScholarK. Inoki, T. Zhu, and K.-L. Guan, “TSC2 mediates cellular energy response to control cell growth and survival,” Cell, vol. 115, no. 5, pp. 577–590, 2003.
View at: Publisher Site | Google ScholarM. Nellist, M. A. Goedbloed, and D. J. J. Halley, “Regulation of tuberous sclerosis complex (TSC) function by 14-3-3 proteins,” Biochemical Society Transactions, vol. 31, no. 3, pp. 587–591, 2003.
View at: Publisher Site | Google ScholarS. D. Shumway, Y. Li, and Y. Xiong, “14-3-3 binds to and negatively regulates the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product, tuberin,” Journal of Biological Chemistry, vol. 278, no. 4, pp. 2089–2092, 2003.
View at: Publisher Site | Google ScholarS. Das, A. Tosaki, D. Bagchi, N. Maulik, and D. K. Das, “Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling,” Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 3, pp. 980–988, 2006.
View at: Publisher Site | Google ScholarH. Ishida, K. Ohkawa, A. Hosui et al., “Involvement of p38 signaling pathway in interferon--mediated antiviral activity toward hepatitis C virus,” Biochemical and Biophysical Research Communications, vol. 321, no. 3, pp. 722–727, 2004.
View at: Publisher Site | Google Scholar